Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251896 | 0.94 | RAB9A (0.57) | RAB9AALDH1A1SMN1; SMN2NPC1MPO | |
| SCHEMBL24251937 | 0.81 | RAB9A (0.49) | RAB9AALDH1A1SMN1; SMN2NPC1MPO | |
| SCHEMBL29388167 | 0.81 | RAB9A (0.49) | RAB9AALDH1A1SMN1; SMN2NPC1MPO | |
| SCHEMBL24313131 | 0.79 | RAB9A (0.47) | RAB9AALDH1A1SMN1; SMN2NPC1MPO | |
| SCHEMBL9967112 | 0.76 | RAB9A (0.56) | RAB9AALDH1A1SMN1; SMN2NPC1MPO | |
| SCHEMBL30082438 | 0.76 | RAB9A (0.56) | RAB9AALDH1A1SMN1; SMN2NPC1MPO | |
| SCHEMBL10267105 | 0.74 | USP30 (0.47) | RAB9AALDH1A1SMN1; SMN2NPC1MPO | |
| SCHEMBL30409070 | 0.73 | RAB9A (0.40) | RAB9AALDH1A1SMN1; SMN2NPC1MPO | |
| SCHEMBL24251902 | 0.73 | RAB9A (0.40) | RAB9AALDH1A1SMN1; SMN2NPC1MPO | |
| SCHEMBL30317982 | 0.72 | RAB9A (0.52) | RAB9AALDH1A1SMN1; SMN2NPC1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096720-B | Dihydropyrrolo [2,3-d ] pyridazin-7-one derivatives, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-115867547-B | 1H-pyrazole-4-amide derivative, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-115485281-B | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-116096720-A | Dihydropyrrolo [2,3-d ] pyridazin-7-one derivatives, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115867547-A | 1H-pyrazole-4-amide derivative, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115485281-A | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022042612-A1 | DIHYDROPYRROLO[2,3-D]PYRIDAZIN-7-ONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-03-03 | — | — | WO | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR3, FGFR1, FGFR4 | RAB9A 3048/4885ALDH1A1 1092/4885SMN1; SMN2 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.